EMT6-PTR tumors had higher total immune scores (Fig. 6A), with activated cytotoxic CD8 + T lymphocyte (CTL) and M2 macrophage scores significantly decreased (Fig. 6B), further suggesting conflicting tumor immune responses may occur after acquired PD-L1 resistance. This evidence concerns the gene CD8A and neoplasm.